Nektar Therapeutics (NKTR) Total Debt (2011 - 2020)

Nektar Therapeutics' Total Debt history runs 10 years deep, the most recent figure standing at $508.9 million for Q1 2020.

• In Q1 2020, Total Debt rose 105.73% year-over-year to $508.9 million; the TTM figure through Mar 2020 stood at $508.9 million (up 105.73% YoY), while the FY2019 annual figure was $252.9 million, up 2.41% from the prior year.
• Total Debt was $508.9 million for Q1 2020 at Nektar Therapeutics, up from $252.9 million in the prior quarter.
• In the past five years, Total Debt ranged from a high of $508.9 million in Q1 2020 to a low of $242.1 million in Q1 2016.
• Historically, Total Debt has averaged $261.2 million across 5 years, with a median of $245.6 million in 2018.
• The sharpest annual moves came in 2019 and 2020: Total Debt gained 0.71% in 2019, then jumped 105.73% in 2020.
• A 5-year view of Total Debt shows it stood at $243.5 million in 2016, then grew by 0.72% to $245.2 million in 2017, then grew by 0.71% to $247.0 million in 2018, then advanced by 2.41% to $252.9 million in 2019, then soared by 101.25% to $508.9 million in 2020.
• The last three Total Debt figures came in at $508.9 million (Q1 2020), $252.9 million (Q4 2019), and $248.3 million (Q3 2019), per Business Quant data.